PrEP Reduces the Risk of Acquiring HIV Infection among Gay and Bisexual Men and Transgender Women Who Have Sex with Men

Estimados colegas , aquí les dejo otro abstract interesante sobre el estudio de profilaxis pre exposición publicado en el NEJM en 2010 diciembre y que el CDC esta comentando el día de hoy.

Saludos 

Dr. Carlos Erazo

A daily dose of an oral antiretroviral drug containing tenofovir plus emtricitabine (brand name Truvada), currently approved to treat HIV infection, reduced the risk of acquiring HIV infection by 44% among men who have sex with men (MSM) and transgender women who have sex with men. The findings, a major advance in HIV prevention research, come from a large international clinical trial known as the iPrEx study published online November 23 by the New England Journal of Medicine. Even higher rates of effectiveness, up to 73%, were found among study participants who adhered most closely to the daily drug regimen. Participants also received a comprehensive package of prevention services, which included use of condoms, monthly HIV testing, counseling, and management of other sexually transmitted infections. Read the full text of Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men.
These findings add to a growing body of knowledge on the use of treatment drugs for HIV prevention. CDC, NIH, and other institutions are conducting ongoing trials to determine the safety and effectiveness of PrEP for injection drug users and heterosexuals at high risk, and those results are expected within the next few years.
To ensure that MSM and their health-care providers have accurate information on PrEP, CDC will publish interim guidance for health-care providers in the coming weeks in the Morbidity and Mortality Weekly Report, followed by formal U.S. Public Health Service guidelines.
CDC will be working with its partners on many additional steps to promote safe and appropriate use of PrEP and determine how to maximize the impact of PrEP in the United States. For the international health community, the World Health Organization (WHO) and the Joint United Nations Programme on HIV/AIDS (UNAIDS) will lead international efforts to develop guidance on implementation. For more information on PrEP and HIV prevention, visit www.cdc.gov/hiv/prep.